<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04010032</url>
  </required_header>
  <id_info>
    <org_study_id>4-2019-0418</org_study_id>
    <nct_id>NCT04010032</nct_id>
  </id_info>
  <brief_title>The Effect of Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion on Postoperative Analgesia in Pediatric Patients</brief_title>
  <official_title>The Effect of Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion on Postoperative Analgesia in Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to compare the efficacy of a programmed intermittent bolus
      injection method compared to conventional continuous infusion in the management of epidural
      analgesia in pediatric patients correctional osteotomy. As a prospective double blinded
      randomized controlled trial, the investigators compare the quality of pain control after
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>triple (Participant, Care Provider, investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in total amount of ropivacaine injected through epidural analgesia</measure>
    <time_frame>6 hours after surgery</time_frame>
    <description>The difference in the amount of ropivacaine injected into epidural space for 6 hours postoperatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in total amount of ropivacaine injected through epidural analgesia</measure>
    <time_frame>12 hours after surgery</time_frame>
    <description>The difference in the amount of ropivacaine injected into epidural space for 12 hours postoperatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in total amount of ropivacaine injected through epidural analgesia</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>The difference in the amount of ropivacaine injected into epidural space for 24 hours postoperatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in total amount of ropivacaine injected through epidural analgesia</measure>
    <time_frame>36 hours after surgery</time_frame>
    <description>The difference in the amount of ropivacaine injected into epidural space for 36 hours postoperatively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in total amount of ropivacaine injected through epidural analgesia</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>The difference in the amount of ropivacaine injected into epidural space for 48 hours postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time for the first patient controlled rescue epidural bolus after surgery</measure>
    <time_frame>48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient-controlled rescue epidural bolus for 48 hours postoperatively</measure>
    <time_frame>48 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores for 6 hours after surgery (VAS)</measure>
    <time_frame>6 hours after surgery</time_frame>
    <description>VAS(visual analogue scale) :0(no paine)~10(wort possible, unbearable, excruciating apin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores for 12 hours after surgery (VAS)</measure>
    <time_frame>12 hours after surgery</time_frame>
    <description>VAS(visual analogue scale) :0(no paine)~10(wort possible, unbearable, excruciating apin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores for 24 hours after surgery (VAS)</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>VAS(visual analogue scale) :0(no paine)~10(wort possible, unbearable, excruciating apin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores for 48 hours after surgery (VAS)</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>VAS(visual analogue scale) :0(no paine)~10(wort possible, unbearable, excruciating apin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores for 6 hours after surgery (r-FLACC)</measure>
    <time_frame>6 hours after surgery</time_frame>
    <description>r-FLACC scale (revised Face, Legs, Activity, Cry, Consolability scale): summation of each items and total range is 0~10. higher values represent a more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores for 12 hours after surgery (r-FLACC)</measure>
    <time_frame>12 hours after surgery</time_frame>
    <description>r-FLACC scale (revised Face, Legs, Activity, Cry, Consolability scale): summation of each items and total range is 0~10. higher values represent a more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores for 24 hours after surgery (r-FLACC)</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>r-FLACC scale (revised Face, Legs, Activity, Cry, Consolability scale): summation of each items and total range is 0~10. higher values represent a more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores for 48 hours after surgery (r-FLACC)</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>r-FLACC scale (revised Face, Legs, Activity, Cry, Consolability scale): summation of each items and total range is 0~10. higher values represent a more severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether to administer additional intravenous narcotic analgesics with total additional intravenous analgesic dose.</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>-% of patients with given intravenous additional narcotic analgesics
number of administrating intravenous additional narcotic analgesics per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether to administer additional intravenous narcotic analgesics with total additional intravenous analgesic dose.</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>-% of patients with given intravenous additional narcotic analgesics
total additional dose of intravenous narcotic analgesics per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether to administer additional intravenous narcotic analgesics with total additional intravenous analgesic dose.</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>-% of patients with given intravenous additional narcotic analgesics
measurement tool: Electronic Medical Record(including Drug administration history)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A dull feeling the patient feels</measure>
    <time_frame>6 hours after surgery</time_frame>
    <description>A dull feeling the patient feels : yes or no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A dull feeling the patient feels</measure>
    <time_frame>12 hours after surgery</time_frame>
    <description>A dull feeling the patient feels : yes or no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A dull feeling the patient feels</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>A dull feeling the patient feels : yes or no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A dull feeling the patient feels</measure>
    <time_frame>48 hours after surgery</time_frame>
    <description>A dull feeling the patient feels : yes or no</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Correctional Osteotomy</condition>
  <arm_group>
    <arm_group_label>PIEB (Programmed intermittent epidural bolus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CEI (Continuous epidural infusion)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Programmed intermittent epidural bolus</intervention_name>
    <description>bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection) using PCA device</description>
    <arm_group_label>PIEB (Programmed intermittent epidural bolus)</arm_group_label>
    <other_name>PIEB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous epidural infusion</intervention_name>
    <description>Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device using PCA device</description>
    <arm_group_label>CEI (Continuous epidural infusion)</arm_group_label>
    <other_name>standard, CEI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Pediatric patients with between 4 and 13 years

          -  2. Patients scheduled for correctional osteotomy of the lower extremity

          -  3. Pediatric patients whose weight of 40kg of less

        Exclusion Criteria:

          -  1. Contraindications to epidural analgesia (local infection, blood clotting disorder,
             anatomical abnormality, sepsis, etc.)

          -  2. Patients with symptoms/signs of elevated intracranial pressure with or without a
             history of elevated intracranial pressure

          -  3. If all of the parents of the subject are foreigners or illiterate (if the parents
             of the subject can not read the agreement)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yong Seon Choi, MD., PhD.</last_name>
    <phone>82-2-2228-2412</phone>
    <email>YSCHOI@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Yong Seon Choi, MD, Ph.D</last_name>
      <phone>82-2-2228-2412</phone>
      <email>yschoi@yush.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

